Many thanks for your continuously support and sharing experience. Here I can share my concerns which previously I don’t know whom I could discuss with.
As shared before, my dad is taking a half dose of Zytiga (500mg/day). We do not know if it is a new approach of not using full dose or because of Zytiga shortage in my country. His doctor said because of high side effects of Zytiga and small size of my country’s people, a half of dose is better. However, she said if we wanted, he could use full dose by self-paying. Currently, the insurance cover 30% of a half dose. I contacted with an oversea source suppling Abirakast and Zytiga. Since the cost of these two is quite different, I would like to get your view and sharing before making a decision.
- Have any of you used Abirakast?
- Do you know the effectiveness of Abirakast in comparison to Zytiga? Is it similar?
- What are the side effects of Abirakast?
- On Emedkit website, it introduces some AA such as (1) – Abirakast; (2) – Abirapro; (3) – Xbira; and (4) – Zeyti. Do you know which of 4 products above is the most popular after Zytiga? Are they all products of India?
- If you have to choose between a half dose of Zytiga (500mg/day) and a full dose of other AA, which one will you choose?
I asked too much but looking forward to hearing from you.
Thank you, I read this article. My dad stated taking 500mg Zytiga /day since last month (first 2 weeks without food and after that with food) but PSA still increases. That's why we have this post.
I have been taking 250 mg of abiraterone with a "low fat" breakfast since my doctor started me it last July. My PSA is unmeasurable and my T is 7. If you follow the link in the above message (pubmed.ncbi.nlm.nih.gov/321...), read the abstract and then go look Fig 1, below it, you will see, if you click on the figure, section 1B, that the NCCN, ver. 2.2019 has incorporated 250 mg of abi with a low fat breakfast as an alternative to the normal 1000 mg methodology.
I have been on 1000mg/day Zytiga since June when my Lupron clearly failed. My options were chemo or Zytiga And I opted for Zytiga. My first month supply was from the original supplier and it knocked my PSA down to 2.9 from 29 ng/dl. Since I pay out of pockets which aren’t terribly deep I had a orchiectomy to eliminate the Lupron expense. My. QOL has been great. Yes I I have budding breasts, but from the front, I look as if I had pretty good pecs.. I do have very annoying hot flushes but I can bring them under a measure of control by taking vegetable or animal estrogen.
The generic arbiterone acetate maintained the low PSA level until recently when it began to rise, but it gave me 9 good months of Life.
Addendum: I get my generic Zytiga from India, this costs $160.00/month. Sometimes there are short gaps in the supply chain and at that time I have taken 500mg with a full fat meal, as opposed to while fasting.
Abirapro and Xbira are from India and so is Zeycte. Not sure if it is the same as Zeyti. Abirakast seems to be a generic from Novartis.
Zytiga is the innovator drug - i.e. the drug originally developed by the pharma company Janssen and approved by the FDA. Usually any newly developed drug is offered patent protection for 10-15-20 years in order for the innovator to recover their R&D expenses and earn some profit. Thereafter upon the patent expirty, using the drug formulation/ receipe of the innovator, other players start manufacturing generic versions of the drug. The contents/Active Ingridient is the same as the innovator drug, the manufacturer is different.
In this case Zytiga is the innovator drug by Janssen whereas the others Abirapro, Zeycte and Xbira are generics manufactured by Glenmark Pharma and Cipla. As the content/API remains the same i.e. Abiraterone Acetate our oncologist has asked us to use any of them.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.